Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$0.68
-2.8%
$1.06
$1.10
$13.78
$1.43M1.81236,278 shs76,447 shs
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.83
+0.8%
$2.07
$1.29
$3.51
$168.69M0.26185,804 shs4,993 shs
MYMX
Mymetics
$0.00
$0.00
$0.00
$0.00
N/A2.37N/AN/A
OMBP
Omni Bio Pharmaceutical
$0.00
$0.00
$0.00
$0.04
N/AN/AN/AN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
0.00%0.00%0.00%0.00%0.00%
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%+13.40%-5.66%+2.82%-84.44%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-1.89%+0.83%-15.97%-4.97%-6.44%
MYMX
Mymetics
0.00%0.00%0.00%0.00%-70.00%
OMBP
Omni Bio Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/AN/AN/AN/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
3.2637 of 5 stars
3.85.00.00.02.71.70.0
MYMX
Mymetics
N/AN/AN/AN/AN/AN/AN/AN/A
OMBP
Omni Bio Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
0.00
N/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00
N/AN/AN/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
3.50
Strong Buy$11.00501.09% Upside
MYMX
Mymetics
0.00
N/AN/AN/A
OMBP
Omni Bio Pharmaceutical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CUR, CRXM, IPHA, MYMX, and OMBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2025
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.50 ➝ $11.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K5.49N/AN/A$6.64 per share0.10
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$21.77M7.75N/AN/A$0.11 per share16.64
MYMX
Mymetics
$1.08M0.00N/AN/AN/A
OMBP
Omni Bio Pharmaceutical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/A0.00N/A-39,417.64%-170.51%-110.16%N/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$53.53MN/A0.00N/AN/AN/AN/A9/17/2025 (Estimated)
MYMX
Mymetics
-$5.06MN/A0.00N/AN/AN/AN/AN/A
OMBP
Omni Bio Pharmaceutical
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/AN/AN/AN/AN/A
MYMX
Mymetics
N/AN/AN/AN/AN/A
OMBP
Omni Bio Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
2.52
2.60
2.60
MYMX
Mymetics
N/AN/AN/A
OMBP
Omni Bio Pharmaceutical
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
0.16%
MYMX
Mymetics
0.73%
OMBP
Omni Bio Pharmaceutical
N/A

Insider Ownership

CompanyInsider Ownership
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
49.80%
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
31.89%
MYMX
Mymetics
5.13%
OMBP
Omni Bio Pharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
3N/AN/ANot Optionable
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
22092.18 million62.78 millionNot Optionable
MYMX
Mymetics
8150,000144,000Not Optionable
OMBP
Omni Bio Pharmaceutical
1N/AN/ANot Optionable

Recent News About These Companies

How AI and omnichannel are transforming pharma marketing
Emphasizing Bio-Pharmaceutical CMC Residue Quality Control
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A
Shanxi Jinbo Bio pharmaceutical Co Ltd 832982
Oversold Conditions For BridgeBio Pharma (BBIO)
Sinopep Allsino Bio Pharmaceutical Co Ltd Class A
Omni-Crawler
Bio-pharma Market Key Players and Forecast till 2031
Zhejiang Wolwo Bio Pharmaceutical Co. Ltd.
BioMarin Pharmaceutical
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cardium Therapeutics stock logo

Cardium Therapeutics OTCMKTS:CRXM

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

Neuralstem stock logo

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Innate Pharma stock logo

Innate Pharma NASDAQ:IPHA

$1.83 +0.02 (+0.83%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Mymetics OTCMKTS:MYMX

$0.0003 0.00 (0.00%)
As of 06/27/2025

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.

Omni Bio Pharmaceutical OTCMKTS:OMBP

$0.0010 0.00 (0.00%)
As of 08/18/2020

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.